Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

M. Diamant, L. Van Gaal, B. Guerci, S. Stranks, J. Han, J. Malloy, M.K. Boardman, M.E. Trautmann

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)464-473
JournalLancet diabetes & endocrinology
Issue number6
Publication statusPublished - 2014

Cite this